



**HAL**  
open science

## Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms

Louise C. Parr-Brownlie, Clémentine Bosch-Bouju, Lucia Schoderboeck, Rachel J. Sizemore, Wickliffe C. Abraham, Stephanie M. Hughes

### ► To cite this version:

Louise C. Parr-Brownlie, Clémentine Bosch-Bouju, Lucia Schoderboeck, Rachel J. Sizemore, Wickliffe C. Abraham, et al.. Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. *Frontiers in Molecular Neuroscience*, 2015, 8, 12 p. 10.3389/fnmol.2015.00014 . hal-02638796

**HAL Id: hal-02638796**

**<https://hal.inrae.fr/hal-02638796>**

Submitted on 28 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms

Louise C. Parr-Brownlie<sup>1,2</sup>, Clémentine Bosch-Bouju<sup>3†</sup>, Lucia Schoderboeck<sup>2,4,5†</sup>, Rachel J. Sizemore<sup>1,2</sup>, Wickliffe C. Abraham<sup>2,5</sup> and Stephanie M. Hughes<sup>2,4\*</sup>

<sup>1</sup> Department of Anatomy, Brain Health Research Centre, University of Otago, Dunedin, New Zealand, <sup>2</sup> Brain Research New Zealand Centre of Research Excellence, Dunedin, New Zealand, <sup>3</sup> NutriNeuro, UMR 1286 INRA, University of Bordeaux, Bordeaux, France, <sup>4</sup> Department of Biochemistry, Brain Health Research Centre, University of Otago, Dunedin, New Zealand, <sup>5</sup> Department of Psychology, Brain Health Research Centre, University of Otago, Dunedin, New Zealand

## OPEN ACCESS

### Edited by:

George Smith,  
Temple University School of Medicine,  
USA

### Reviewed by:

Nicole Déglon,  
Lausanne University Hospital – Centre  
Hospitalier Universitaire Vaudois,  
Switzerland  
Amy Lasek,  
University of Illinois at Chicago, USA

### \*Correspondence:

Stephanie M. Hughes,  
Department of Biochemistry, Brain  
Health Research Centre, University  
of Otago, P.O. BOX 56,  
Dunedin 9054, New Zealand  
stephanie.hughes@otago.ac.nz

† These authors have contributed  
equally to this work.

**Received:** 23 February 2015

**Accepted:** 30 April 2015

**Published:** 18 May 2015

### Citation:

Parr-Brownlie LC, Bosch-Bouju C,  
Schoderboeck L, Sizemore RJ,  
Abraham WC and Hughes SM (2015)  
Lentiviral vectors as tools  
to understand central nervous system  
biology in mammalian model  
organisms.  
*Front. Mol. Neurosci.* 8:14.  
doi: 10.3389/fnmol.2015.00014

Lentiviruses have been extensively used as gene delivery vectors since the mid-1990s. Usually derived from the human immunodeficiency virus genome, they mediate efficient gene transfer to non-dividing cells, including neurons and glia in the adult mammalian brain. In addition, integration of the recombinant lentiviral construct into the host genome provides permanent expression, including the progeny of dividing neural precursors. In this review, we describe targeted vectors with modified envelope glycoproteins and expression of transgenes under the regulation of cell-selective and inducible promoters. This technology has broad utility to address fundamental questions in neuroscience and we outline how this has been used in rodents and primates. Combining viral tract tracing with immunohistochemistry and confocal or electron microscopy, lentiviral vectors provide a tool to selectively label and trace specific neuronal populations at gross or ultrastructural levels. Additionally, new generation optogenetic technologies can be readily utilized to analyze neuronal circuit and gene functions in the mature mammalian brain. Examples of these applications, limitations of current systems and prospects for future developments to enhance neuroscience knowledge will be reviewed. Finally, we will discuss how these vectors may be translated from gene therapy trials into the clinical setting.

**Keywords:** lentivirus, temporal and spatial specificity, neuron phenotype, optogenetics, confocal and electron microscopy

## Recombinant Lentiviruses in Neuroscience

Lentiviral biology has been extensively studied since the early 1980s following evidence that human immunodeficiency virus (HIV) was the causative agent of AIDS. Harnessing aspects of this knowledge, gene therapy researchers developed recombinant viral vectors based on HIV (Verma and Somia, 1997; Naldini, 1998), feline, and equine equivalents. Lentivirus is a member of the *Retroviridae* family of viruses, named because reverse transcription of viral RNA genomes to DNA is required before integration into the host genome. Unlike other retroviral genera, such as gamma-retroviruses that are also used in gene therapy, lentiviruses are able to infect both dividing and non-dividing cells by virtue of the entry mechanism through the intact host nuclear envelope

(Naldini, 1998; Vodicka, 2001). This characteristic makes it an ideal viral vector for neuroscience, where the majority of cells in the postnatal brain do not divide.

Lentiviral genomes are single-stranded RNA with *gag*, *pol* and *env* genes encoding polyprotein components of the capsid, the enzymes reverse transcriptase, protease and integrase, and envelope glycoproteins, respectively. The viral genome is flanked by long terminal repeats (LTRs), required for genome replication and integration (Naldini, 1998). Lentiviruses have additional accessory genes, but these are dispensable in recombinant vectors. Instead, a recombinant lentiviral vector genome contains LTRs flanking a packaging signal, plus an exogenous promoter used to express a transgene that enables identification of subpopulations of cells, overexpression or knockdown of genes or to target cells with a drug- or light-inducible protein to analyze cell function (Dull et al., 1998). The genome capacity is 8–10 kb for maximal packaging efficiency and viral particles are packaged in human cell lines (usually HEK293 derivatives) by co-transfection of helper plasmids encoding *gag*, *pol*, and *env* (Dull et al., 1998). In post-mitotic cells, lentiviral vectors integrate at random, whereas integration preferentially occurs into active genes in mitotically active cells (Bartholomae et al., 2011). An alternative and additional safety aspect for post-mitotic cell transduction is the development of integrase deficient lentiviral vectors (Liu et al., 2014). Removal of the integrase from the packaging construct prevents integration, resulting in episomal maintenance of the transgene vector in post-mitotic cells. Recombinant lentiviral vectors appear to offer greater safety over gamma retroviral vectors in which activation of oncogenes has been reported (Hacein-Bey-Abina et al., 2003; Zhou et al., 2010). Although lentiviral vectors have some limitations, mainly in respect to limited spread within the brain parenchyma, this provides an additional advantage in some cases. Permanent integration of lentiviral delivered transgenes into mitotic or post-mitotic cells, similar to episomal maintenance of integrase-deficient lentivirus or AAV in post-mitotic cells, should allow stable transgene expression for the life of the organism or cell, preventing the need for repeated vector administration (Linterman et al., 2011). An important advantage of lentiviral vectors over other vector systems, including adeno-associated virus (AAV), is that inflammatory, and immune responses associated with the vector itself are limited (Abordo-Adesida et al., 2005; Annoni et al., 2007).

This review highlights how lentiviral vectors have been used in neuroscience research. We focus on targeting gene expression to selected neuronal phenotypes, both spatially and temporally, to answer specific biological questions surrounding gene function and the anatomy and physiology of neural circuits in the mature brain.

## Targeting Gene Expression to Structures and Cells

The design of lentiviral vectors has increased in complexity over the last 20 years. As lentiviral vectors have been used as a tool to address more refined neuroscience questions, expectations for increased spatial and temporal accuracy of gene expression have

resulted, making it more challenging to design new lentiviral vectors for cutting edge experiments.

Transgene expression can be restricted (i) to certain structures or cell types for refined spatial resolution, (ii) in a constitutive or inducible manner for temporal resolution, and (iii) by activation of the gene product by additional stimuli like light or drugs (post-translational regulation). Below we outline how these restrictions are routinely used to improve knowledge of brain circuitry.


### Spatial Restriction of Gene Expression

In its simplest form, spatial restriction of gene expression is achieved by injecting low volumes and/or titres of the lentiviral vector in the target brain region where its spread will be restricted depending on its tropism and diffusion through the target tissue. Lentiviral tropism is defined by the glycoproteins on the surface of the viral particles that determine which cell surface receptor the virus binds to and thereby the cells or subcellular compartments the virus can enter. Tropism can be modified by pseudotyping, which is the expression of glycoproteins originating from a different virus (Indraccolo et al., 1998; Cronin et al., 2005; Tralbalza et al., 2013). The most common pseudotyping method uses the vesicular stomatitis virus glycoprotein (VSVg). VSVg pseudotyped particles have wide tropism as they use low-density lipoprotein receptors to enter cells (Finkelshtein et al., 2013), which are almost ubiquitously expressed on cell membranes (Willnow, 1999), including by both glia and neurons (Jakobsson et al., 2003). By differential pseudotyping, specific populations of neurons within a brain region can be targeted (**Figure 1A**). An example of differential tropism is in the hippocampus, where VSVg pseudotyped vectors mainly transduce cells in the subgranular zone and dentate granule cell layer, while murine leukemia virus glycoprotein (MuLV) pseudotyped vectors more specifically transduce mature granule cells (Watson et al., 2002).

Unlike AAVs, which have a diameter of approximately 20 nm, the larger particle size of lentiviruses (100 nm) limits spread through the extracellular space (Cetin et al., 2006; Lerchner et al., 2014; **Figure 1**), and methods to increase AAV spread, like convection-enhanced delivery or mannitol, are therefore not promising for lentiviral particles. The spread of one microliter of VSVg pseudotyped vector in the brain is restricted to 1–2 mm from the injection site (Desmaris et al., 2001; Linterman et al., 2011), with no retrograde transport. By exchanging the VSVg for a rabies glycoprotein (Rbg; Mazarakis et al., 2001), or a chimera of these two (Kato et al., 2011a,b, 2014; Carpentier et al., 2012; Schoderboeck et al., 2015) retrograde transport is enabled so that after transduction of axonal terminals, viral contents (minus envelope) are transported to the cell body (**Figure 1**).

### Cell-Specific Gene Expression Using Promoters

The promoter controlling gene expression in the lentiviral construct provides a further level of restriction. In addition to ubiquitous promoters, a range of brain cell-type specific promoters are available and well characterized. A list of promoters that are frequently used in neuroscience research is detailed in **Table 1**. Ubiquitous promoters that cause expression of non-native



proteins in virtually all transduced cells include elongation factor 1 alpha (EF1 $\alpha$ ), cytomegalovirus enhancer/promoter element (CMV),  $\beta$ -actin,  $\beta$ -globin chimeric promoter (CAG), and phosphoglycerate kinase promoter (PGK; for a comparison see

(Qin et al., 2010) and (Yaguchi et al., 2013). Promoters providing specific expression in all neurons include synapsin 1 (syn; Hioki et al., 2007; Nathanson et al., 2009; van Hooijdonk et al., 2009; Yaguchi et al., 2013) and neuron specific enolase (NSE;

**TABLE 1 | Commonly used promoters in lentiviruses.**


Common abbreviation	Promoter origin	Expressed in	Comments
EF1 $\alpha$	Mammalian elongation factor 1 alpha promoter	Ubiquitous	Endogenous mammalian promoter (Jakobsson et al., 2003).
CMV	Human cytomegalovirus immediate-early enhancer/promoter	Ubiquitous	Methylation-dependent silencing of transgene expression (Brooks et al., 2004)
CAG	CMV coupled with chicken $\beta$ -actin promoter and first exon and rabbit $\beta$ -globin splice acceptor.	Ubiquitous	Stable long term expression (Jakobsson et al. (2003), Delzor et al. (2012)).
PGK	Mammalian phosphoglycerate kinase 1 promoter	Ubiquitous	Endogenous mammalian gene Delzor et al. (2012)
MND	Myeloproliferative sarcoma virus enhancer, Negative control region deleted, dl587rev primer-binding site substituted	Ubiquitous	Li et al. (2010), Linterman et al. (2011)
Syn	Mammalian synapsin 1 promoter	Neurons	Dittgen et al. (2004)
GAD67	Mammalian glutamate decarboxylase 67	Inhibitory neurons	Nathanson et al. (2009), Delzor et al. (2012)
CaMKII $\alpha$	Mammalian calcium/calmodulin-dependent protein kinase II alpha promoter	Excitatory glutamatergic neurons	Postnatal expression – later in development than synapsin (Dittgen et al., 2004; van Hooijdonk et al., 2009).
NSE	Mammalian neuron-specific enolase promoter	Neurons	Relatively weak expression (Delzor et al., 2012)
MBP	Mammalian myelin basic protein promoter	Oligodendrocytes	McIver et al. (2005, 2010)
GFAP	Mammalian glial fibrillary acidic protein promoter	Astrocytes	Higher expression in activated astrocytes (Chow et al., 2008).
Nes	Mammalian nestin promoter	Neural progenitor cells	Can also be expressed in activated astrocytes. (Beech et al., 2004; Cheng et al., 2004; Sun et al., 2014).

Delzor et al., 2012). Neuronal type specific promoters, that have a size compatible with lentiviral vectors are still limited, but include calcium/calmodulin-dependent protein kinase II alpha (CaMKII $\alpha$ ; Dittgen et al., 2004; van Hooijdonk et al., 2009; Seeger-Armbruster et al., 2015), which restricts expression to excitatory glutamatergic neurons and glutamate decarboxylase 67 (GAD67; Delzor et al., 2012) that should restrict expression to inhibitory GABAergic neurons. The parvalbumin promoter targets a subset of GABAergic neurons (Sohal et al., 2009) and ppHcr1 targets hypocretin neurons (Zhang et al., 2010). However, because LV-VSVg has strong tropism for excitatory neurons, transgene expression from the GAD67 promoter has also been found in excitatory neurons (Nathanson et al., 2009). The glial fibrillary acid protein (GFAP) promoter is most commonly used to restrict gene expression to astrocytes (Jakobsson et al., 2003), myelin basic protein (MBP) to target oligodendrocytes (McIver et al., 2005), and the nestin (nes) promoter for neural progenitor cells (Beech et al., 2004). The specificity of these promoters is not absolute and can be impaired by viral preparation properties (titre) and promoter properties in certain subregions of the brain. Promoters used in lentiviral vectors typically only comprise minimal promoter sequences, while their endogenous counterparts are often significantly longer and more complex including enhancer and insulator elements. Using a minimal promoter sequence simplifies cloning and helps keep the vector size small, but this also compromises the specificity as parts of the promoter or enhancer and insulator elements will be missing. Integration of vectors close to enhancer or repressor sequences can also impact vector promoter fidelity.

Tighter cell-type specificity can be achieved by combining lentiviruses with the cre-lox system in transgenic animals. The system involves two components: cre recombinase and a transgene flanked by lox sites ("floxed"), the recognition sites for cre recombinase. The bacterial cre protein uses the lox sites for site-specific recombination in mammalian cells (Sauer and Henderson, 1988). Both components can be supplied by viral vectors or a transgenic animal used to express either cre recombinase, or a floxed transgene; either of which can be controlled by a cell-type specific promoter (Figure 2). The lentiviral vector supplies the other component (cre or floxed transgene), which might include a protein under posttranslational regulation (See Posttranslational Control of Gene Expression).

Conditional knockdown of gene expression is another powerful method to analyze protein function in the adult brain. microRNA (miRNA)-based short hairpin knockdown can be combined with cell specific promoters (Nielsen et al., 2009), or used in combination with cre-lox or drug-inducible cre-lox systems for spatial and temporal control of gene knockdown (Stern et al., 2008; Heitz et al., 2014). For example, Heitz et al. (2014) use a lentiviral vector expressing a floxed GFP miRNA to transduce mice expressing GFAP or CaMKII regulated tamoxifen-inducible cre (creERT2).

Further restriction of gene expression can be achieved by miRNA de-targeting. In this system, incorporating miR binding sites into the 3' UTR of transgene constructs within a viral vector limits expression to those cells that do not express that miR.



For example, miR-9 is expressed in all cells in the brain with the exception of microglia. By incorporating miR-9 binding sites into the transgene construct, miR-9 will bind to, and degrade transgene RNAs in all cells except microglia, resulting in selective expression of the transgene in microglia (Akerblom et al., 2013). Similarly, preventing transgene expression in neurons, and enhancing astrocyte expression can be aided by incorporation of the miR-124 binding sequences into the vector (Colin et al., 2009). As further advances in understanding miR biology and cell type specificity emerge, these constructs can be further refined for selective gene expression.

### Temporal Control of Gene Expression

Temporal control of gene expression is achieved using inducible promoters. These promoters are activated by an additional factor that is added to or removed from the system. They are widely used in bacterial expression systems and include promoters controlled by drugs, metal ions, heat shock, or hormones – only some of which are useable in mammalian cells, and even fewer in the CNS where drugs need to cross the blood brain barrier. Most commonly, drug-inducible promoters are used in neuroscience, where the transgene is expressed under the control of a minimal promoter sequence that is only active if bound by a transactivator. The ability of this transactivator to bind the promoter is regulated by co-factors. The most famous and widely used inducible promoter system is the Tet-On/Off system and derivatives thereof. In this system, the transgene is downstream of a minimal promoter under the control of a Tet response element (TRE) based on an *Escherichia coli* operon conferring resistance to the antibiotic tetracycline. For use in mammalian cells, the Tet repressor (Tet-On) is fused to the activating domain of virion protein 16 of herpes simplex virus (VP16) that constitutes the tetracycline-controlled transactivator (tTA). When tTA binds to the TRE, transcription from the minimal promoter is



stimulated by tetracycline or its derivative doxycycline (DOX) in a concentration-dependent manner, thus providing a reversible on and off switch (Gossen and Bujard, 1995; Gossen et al., 1995; Pluta et al., 2005). In the Tet-Off system, the tTA binds to the TRE in the absence of tetracycline and activates gene expression; when tetracycline or DOX is administered, gene expression is repressed (Gossen and Bujard, 1992). The Tet-On system was derived by mutation of the tTA leading to the opposite phenotype, where administration of tetracycline induces gene expression (Gossen et al., 1995).

Light-inducible promoters have recently expanded the potential of inducible promoters (Wang et al., 2012). In a system similar to the Tet concept, a photoactivatable transactivator dimerises upon exposure to light of a certain wavelength, permitting it to bind to its response element and thereby induce gene expression. The advantages of this optogenetic system over drug-inducible promoters are the higher spatial and temporal accuracy of induction and reversibility (ms to s resolution), whereas tetracycline (and DOX) is usually delivered systemically and its effects can last from hours to days (Agwuh and MacGowan, 2006).

Some specific research questions require tight spatial and temporal control of gene expression and aim to express the transgene in only a specific subset of very similar cells, which can be optimally addressed by combining several techniques. Studying neurogenesis in the adult mammalian brain requires several techniques to be combined to obtain the necessary specificity. In order to only target newborn granule cells, which are very similar to their developmentally born neighboring granule cells, a cre transgenic mouse can be combined with cell-type specific promoter (Figure 2). The transgenic mouse expresses cre recombinase under a nestin promoter only present in neural progenitor cells, which reside in the subgranular and subventricular zones in the hippocampus. To only target newly born cells in the hippocampus, a VSVg-pseudotyped lentivirus with the transgene is injected into the dentate gyrus; in Figure 2, the transgene encodes the fluorescent protein mCherry. The transgene is inverted and flanked by two sets of loxP sites to prevent leaky expression in cells without cre recombinase. By placing the transgene under a syn promoter, it will only be expressed in mature neurons born after the injection of the lentivirus. Including a Tet system to induce cre expression only at very specific time points could further enhance temporal resolution (Chen et al., 2009).

## Posttranslational Control of Gene Expression


Posttranslational regulation of transgene expression can be used to control neural activity by using reversibly activatable ion channels or G-protein coupled receptors (GPCR; reviewed in Rogan and Roth, 2011). The expressed channels and GPCRs are responsive to either light or drugs. Below we focus on the utility of light (optogenetic stimulation) to alter cell function or structure because it has the most accurate (shortest) time resolution (ms) and can mimic the time course of real neural activity. However, sophisticated, highly specific and activatable changes in gene expression can occur over longer time frames using drugs

(min-days), so are ideally suited for examining biological states such as circadian rhythm, sleep-wake cycle, stress, and the control of feeding. One of the most recent advances is to completely isolate the introduced transgene from the endogenous ligand-GPCR combinations by developing designer receptors exclusively activated by designer drugs (DREADDs; Armbruster et al., 2007). One advantage of DREADDs is that both receptors and ligands are specifically designed to have high affinity to each other, but not with other targets *in vivo*.

## Light Inducible Control of Neuronal Function – Optogenetics

In the field of neuroscience, a major new application of lentiviral vectors has been the development of optogenetic technology. Optogenetic stimulation (optogenetics) is the result of 30 years of intense research in both gene therapy and light-activated proteins. Since the first article in 2005 describing the use of optogenetics in neuroscience (Boyden et al., 2005), optogenetics has genuinely revolutionized neuroscience research and the number of publications using optogenetics has increased exponentially (Aston-Jones and Deisseroth, 2013). Optogenetics was chosen as the method of the year by the prestigious Nature Methods journal in 2010.

The principle of optogenetics is to express a light-activated protein in brain cells via a viral vector, such as a lentivirus, and then activate this particular population of brain cells with light of a specific wavelength (Figure 3A). The power of optogenetics resides in its spatial, temporal, and neuronal phenotype specificity to control brain cells (Fenno et al., 2011), which was previously lacking despite many attempts to solve it using other neuroscience methods. Precise timing of optogenetic stimulation is achieved by light pulses [using a laser or light emitting diode (LED) as a light source and to deliver the light at a target area of the brain using an optical fiber], at millisecond resolution, which is in accordance with rapid generation and transmission of action potentials at the initial segment or along the axon. Spatial specificity is achieved by locally injecting the viral vector into a specific part of the brain and restricting its spread to only the target nucleus by optimizing the number of injections and volume injected at each site to match the three dimensional shape of the target. In cases when a target site has a neuronal phenotype that differs from surrounding nuclei, spatial specificity is also achieved by using a promoter for that neuronal phenotype. Spatial specificity can be further enhanced by careful positioning of the fiber optic probe for controlled application of light within the target nucleus. Transduction of a specific population of neurons is achieved by pseudotyping viral vectors and promoters as described in Section “Spatial Restriction of Gene Expression” and “Cell-Specific Gene Expression Using Promoters,” respectively. Temporal control of channel activity is dependent on activation of the laser. At first, optogenetics was used to replace electrical stimulation because it achieves the goal of activating specific neuronal circuits to understand how they work with significantly improved accuracy. In contrast, electrical stimulation has the major drawback of activating all excitable tissues in the area, including passing fibers (Bosch et al., 2011). Since 2005, the tools for optogenetics (types and properties of light-activated



proteins, promoters, viral vectors, light sources, stimulation, and recording devices) have been rapidly developing enabling scientists to create new paradigms and innovative approaches to address complex scientific questions. In particular, optogenetics can be used to dissect the anatomy and function of neuronal circuits (Atasoy et al., 2012) and induce or restore behaviors (Fanselow and Connors, 2005; Chaudhury et al., 2013; Seeger-Armbruster et al., 2015; **Figures 3B,C**). Moreover, while electrical stimulation has been focused on controlling neuronal activity, optogenetics also allows manipulation of glial cells (astrocytes, microglia), which constitutes an incomparable way to understand the role of glia in the brain (Figueiredo et al., 2011; Li et al., 2013).

More recently, optogenetics has evolved beyond controlling cell excitability (ion channels). Light-activated proteins are able to activate downstream signaling pathways, for example OptoXR, a category of light-activated proteins that are able to activate signaling pathways from G<sub>q</sub>, G<sub>s</sub>, or G<sub>i</sub> proteins when they are activated by 500 nm-light (Fenno et al., 2011). A photoactivatable version of adenylyl cyclase is also available, which has notably been used to increase levels of glucocorticoids to study stress responses in zebrafish (De Marco et al., 2013). Optogenetics can also work by dimerization or interactions of the light-activated proteins upon light stimulation, which can control an almost infinite variety of signaling pathways and have been used notably to trigger cell migration (Pathak et al., 2013).

Lentiviruses were chosen as the viral vector for the first article describing optogenetics (Boyden et al., 2005). Currently, most studies use either lentiviruses or AAVs as the vector of choice in rodents or monkeys. Despite differences in their transduction, specificity, and spread in the brain (**Figure 1**), the selection of one or other vector is rarely explained in research articles. The main difference between lentivirus and AAV is their ability to diffuse in the brain (Packer et al., 2013). Indeed, AAV transduces a much larger area around the injection site compared to lentivirus, which is usually restricted to the site of injection (**Figure 1**). As a consequence, AAVs are preferred when high expression levels of light-activated proteins are needed in a large area of the brain. AAV also seems to cause higher expression at the cell level by inserting a larger number of copies into each cell (Diester et al., 2011); however, this may not be advantageous. Recent studies suggest that high level of gene transfer with AAV increases the probability of developing aggregates of non-native expressed proteins in cells (Diester et al., 2011) and/or axonal malformation (Miyashita et al., 2013). This is less likely to occur with lentivirus, due to the lower level of transduction. Moreover, high levels of light-activated proteins lead to higher stimulation rates, which can lead to artificial effects and thus bias the conclusions (Hausser, 2014). In contrast, lentiviruses are preferred when spatial specificity is needed, despite lower levels of expression, and when the genetic code for expression of the required protein is large. In mice where transgenic technologies are well established, optogenetics is commonly performed with transgenic mice in combination with AAV, using the cre-lox system. In this configuration, spatial specificity is achieved by the injection of a floxed transgene construct and high level of expression is achieved by using AAV. Overall, the choice of viral vector is complex and depends on the experimental design required to answer the research question and it is particularly important because many optogenetic studies are performed on freely moving animals, addressing complex behavioral questions over weeks or months.

In the few studies performing optogenetics in monkey, lentivirus and AAV have both been used successfully (Han et al., 2009; Diester et al., 2011; Galvan et al., 2012; Lerchner et al., 2014) with the difference that lentivirus leads to a smaller proportion of aggregates and may thus be a better option for long term studies, as is usually the case with monkeys.

In the future, optogenetics may evolve towards more specific stimulation of neuronal populations with fewer side effects, and


lentiviral tools may play a key role in this. For basic neuroscience research, one of the ultimate goals of optogenetic stimulation techniques is to mimic activity in a normally functioning neuronal network to understand the neuronal coding responsible for brain function (Seeger-Armbruster et al., 2015). Another perspective is to use optogenetics with very specific patterns of light stimulation (such as theta burst stimulation in the cortex) to promote plasticity and restore normal behavior in a brain with a neurological disorder (Seeger-Armbruster et al., 2015). A potential future extension of optogenetics will be its use in humans. Although lentivirus has a limited transduction capacity compared to AAV, this is less important when combined with optogenetic stimulation because that the area of brain transduced by the vector and stimulated by the fiber-optic probe are of similar size. From this perspective, lentivirus may be preferred for optogenetic stimulation to treat or cure neurological diseases in humans in the future because of its specificity and limited long-term toxicity on brain tissue.

### Exploring Neuronal Circuitry in the Brain

Another field being redefined by lentiviral vectors is neural tracing. Lentivirus provides several advantages with spatially defined expression and combinations of tracers with optogenetic and other functional constructs allowing examination of questions not previously possible using traditional tracing techniques.

Analysis of neuronal circuitry has traditionally relied on neuronal tracers such as biotinylated dextran amine (BDA), phaseolus vulgaris leucoagglutinin (PHAL), wheat-germ agglutinin (WGA), horseradish peroxidase (HRP), cholera toxin, and more recently pseudorabies virus to label neuronal pathways (Callaway, 2008; Huh et al., 2010). Some of these tracers label neurons in a predominantly anterograde [high molecular weight (Mr) BDA, PHAL] or retrograde (low Mr BDA, pseudorabies, cholera toxin, HRP), or bidirectional (WGA) way. While these tracers confer spatial specificity that is dependent on the volume injected, all neurons in the injected region are labeled regardless of the phenotype.

More recently, lentiviral vectors have been combined with microscopy and other biological techniques to investigate the anatomy of neural circuits in many brain areas, including the cerebral cortex, thalamus, basal ganglia, hippocampus, and brainstem (Trono, 2000; Vigna and Naldini, 2000; Duale et al., 2005; Grinevich et al., 2005; Benzekroufa et al., 2009; Huh et al., 2010; Takada et al., 2013; **Figure 4**). Depending on the lentivirus type and the promoter used in the construct, viral vectors can transduce dendrites, the somata, and terminals of neurons and express proteins at a particular subcellular component, such as in the cell membrane or nucleus (Klein et al., 1998; Gradinaru et al., 2010; Lobbstaël et al., 2010; Konermann et al., 2013; Dautan et al., 2014). With careful experimental design, viral vectors can accurately label a particular neuronal phenotype, which affords the possibility of labeling just one distinct pathway in the brain (Tye and Deisseroth, 2012; Dautan et al., 2014; Hasegawa et al., 2014). In addition to spatial specificity, viral vectors allow temporal specificity in neuroanatomy studies, determined by the time of injection and harvesting of tissue (Dull et al., 1998;



Takada et al., 2013). In contrast, immunohistochemistry labels all neurons of a phenotype irrespective of the pathways that they belong to and only selected brain slices are stained and analyzed, which means that neurons of interest are only partially visualized (e.g., axon and terminals, but not somata and dendrites, or the converse), unless large numbers of serial sections are analyzed. Viral vectors permit neurons to be transduced in a controlled area of the brain (Huh et al., 2010) because they diffuse smaller distances than traditional neuronal tracers, however, transduction of large populations of neurons can be achieved by injecting a larger volume, injecting multiple times or using a higher titre



(Miyoshi et al., 1997; Cai et al., 2013). Furthermore, it is possible to combine viral vectors with conditional systems so that neurons are labeled during a specific period of development (Dull et al., 1998; Wiznerowicz and Trono, 2003). Helper-viruses have also been used in short-term anatomical experiments to specifically label excitatory and inhibitory pathways to better understand whole circuits and to improve cloning capacity (Kumar-Singh, 2008; Liu et al., 2013). For all of these reasons, viral vectors permit unprecedented precise descriptions of pathways and connections for subpopulations of neurons.

As described in Section “Spatial Restriction of Gene Expression,” lentiviral vectors can be pseudotyped with envelopes that modify vector uptake, allowing neuronal tracing studies to be conducted. VSVg-pseudotyped vectors transduce neurons and astrocytes only within the local injection site. Delivery of a cytoplasmic-localized transgene via a VSVg-lentivirus will result in labeling of cell soma within the injection site and fills their projections, allowing tracing of neural target zones. In contrast, Rbg-pseudotyped lentiviral vectors deliver transgenes both locally and via retrograde transport to distal somata with axonal projections localized in the injection zone (Mazarakis et al., 2001; **Figure 1**). The transgene-encoded protein is expressed by transduced neurons – the precise site of expression (e.g., axon, nucleus, cell membrane, histone residues of DNA, etc.) is dependent on where the targeted protein is usually located in the cell. This labeling specificity can be critical because of the complexity of the brain. Here, lentiviral vectors offer improved specificity because most AAV serotypes would label both afferent and efferent neurons in the region (Klaw et al., 2013; **Figure 1**). In addition, the flexibility to have the vectors endocytosed at the terminals or somata of target neurons means that the investigator can select the vector so that injection and uptake is in an area that will not be visualized (Schoderboeck et al., 2015; **Figure 4A**). The advantage for experiments with an anatomical focus is that the physical damage or artifact caused by the injection does not interfere with the interpretation or analysis of images taken at high-resolution, such as electron microscopy. For example, if the somata of neurons will be visualized, injection damage will be minimized by targeting uptake at the terminals of the neurons of interest by using a vector containing a Rbg envelope. Conversely, if the terminals will be visualized, the injection should be targeted at the somata of the neurons of interest by using a VSVg envelope.

Neuroanatomy studies using lentiviral vectors can also be enhanced by combining with other techniques. Generally, the reporter fluorophores expressed by transduced neurons are imaged *post-mortem* using fluorescence or confocal microscopy, and often immunohistochemical staining is conducted to confirm that a subpopulation of neurons has been transduced. However, these techniques can be further exploited to determine which cellular compartments express the proteins (Pastrana, 2011; Konermann et al., 2013), for example using epitope tags (Lobbestael et al., 2010), or to detect structural elements, such as synapses, that cannot be definitively determined using light microscopy (Shu et al., 2011; Galvan et al., 2012). Improved tissue clearing techniques (Hama et al., 2011; Chung et al., 2013; Ke et al., 2013) and microscope optics have enabled visualization

of transduced neurons in whole brains, and although this has been done using AAVs so far (Deisseroth and Schnitzer, 2013; Tomer et al., 2014; Yang et al., 2014), lentiviral vectors could be used to provide greater spatial specificity. Electron microscopy is another option that permits visualization of small structural elements and subcellular compartments to investigate circuitry at the ultrastructural level. This can be achieved by immunohistochemically tagging the fluorophore expressed by the viral vector and labeling it with an electron dense chromogen such as intensified diaminobenzidine (DAB, **Figure 4B**), using a genetic tag (miniSOG) that polymerizes DAB when exposed to blue light, or application of immunogold particles during postmortem tissue processing (Grinevich et al., 2005; Sosinsky et al., 2007; Scotto-Lomassese et al., 2011; Shu et al., 2011; Galvan et al., 2012; Dautan et al., 2014; Pollock et al., 2014). By combining lentiviral vectors, optogenetic stimulation, and cutting edge processing techniques for electron microscopy, such as high pressure freezing, the impact of changes in physiology on anatomical circuits can be investigated (Watanabe et al., 2014). Furthermore, because lentiviral vectors produce little to no immune or inflammatory response compared to many other vectors (Blomer et al., 1997), they maintain normal morphology and cellular composition in the area to be investigated, which is critical for studies at the ultrastructural level. This technology could be extended to examine the consequence of activating a G-protein by optogenetic stimulation and imaging how that changes the location of proteins in neurons, thus providing a greater understanding of the function and interactions of proteins at the subcellular level (Pastrana, 2011; Konermann et al., 2013). Thus, viral vectors and lentiviruses in particular, have broad utility to investigate neural circuits at synapse, neuronal, and complete circuit levels.

Importantly, the anatomy of brain circuitry can also be explored *in vivo* by imaging neurons transduced by a viral vector *in situ* using functional magnetic resonance imaging (fMRI) or bioluminescence. Bioluminescence imaging *in vivo* requires a reporter gene to encode a bioluminescent enzyme that generates light, usually in yellow-infrared spectral wavelengths, which are detected by the biosensor without using invasive procedures (Massoud et al., 2008; Shah et al., 2008). Generally, imaging of structures deep within an animal or tissue block is facilitated by having a longer wavelength (Contag and Bachmann, 2002; Zhang et al., 2007). Bioluminescence imaging is limited by its low resolution because light is scattered in body tissues; however, this imaging does provide valuable structural information within an animal (Contag and Bachmann, 2002). Bioluminescence imaging has been used to investigate therapeutic applications of gene expression using AAV, (Contag and Bachmann, 2002), adenovirus (Cho et al., 2005; Massoud et al., 2008), and lentiviral vectors (Deroose et al., 2006). Combining optogenetic stimulation of transduced neurons with fMRI offers a greater understanding of how neural activity alters blood oxygen level dependent (BOLD) signals at stimulated and downstream sites (Adriani et al., 2010; Lee et al., 2010; Desai et al., 2011; **Figure 4C**). In addition, positron emission tomography (PET) has been used to image changes in brain glucose metabolism following optogenetic stimulation to examine functionally connected brain

structures (Thanos et al., 2013). Neurons transduced with lentiviral vectors express non-native proteins for at least 6 months (Blomer et al., 1997), enabling changes in structure to be assessed over long periods of time, thus may provide insights to disease processes, for example, changes in structure associated with animal models of neurodegenerative diseases such as Alzheimer's. An alternative method to trace transduced neurons in more superficial areas of the brain *in situ* is to create a window for imaging transduced neurons via multiphoton microscopy. This usually involves live cell imaging to explore when and how large populations of neurons interact as a network (Shah et al., 2008; Mittmann et al., 2011; Knöpfel, 2012), but could be extended to investigate anatomical studies over time.

In the future, there are many ways that lentiviral vectors could be combined with imaging techniques and exploring these possibilities will greatly improve knowledge of the anatomy of neural circuits. Some applications may include optogenetic stimulation and clearing post-mortem tissue to examine a circuit within large blocks of brain for imaging using confocal microscope. Alternatively optogenetic stimulation combined with high pressure freezing of the tissue and electron microscopy would permit activity-dependent changes in ultrastructural circuitry to be investigated. Enhancing the resolution of *in situ* imaging by fMRI or bioluminescence would greatly improve knowledge of how circuitry changes over time in animal models of neurodegenerative diseases. Future improvements might include development of brain bow-like technology (Weber, 2012) using lentiviral vectors so that multiple pathways and neuronal phenotypes can be investigated in whole brains. The exciting prospect is to explore new combinations of lentiviral gene therapy with optogenetic stimulation, tissue processing, and imaging to address previously unprecedented neuroscience questions about health and disease.

## Current Limitations and Future Prospects

Our understanding of the brain is rapidly expanding. Sophisticated technologies allow us to answer complex questions, understand gene function, and visualize the anatomy of neural

circuits. The use of viral vectors is enhancing much of this work. Viral vectors have developed substantially from basic gene addition or knockdown with constitutive promoters to drug and light regulation of gene and protein expression. Further refinements of vectors, promoter regulation and transgenes continue. One recent example illustrating the potential of vectors in neuroscience involves mind-controlled gene regulation (Folcher et al., 2014). Combining EEG recorded brain waves and a computer interface, gene expression and/or optogenetic channel activity can be remotely regulated and changes in behavior can be measured. While this is currently in the proof-of concept phase, such technology has huge implications for the treatment of many brain disorders including epilepsy and Parkinson's disease.

Clinically, lentiviral vectors have predominantly been used to transduce cells *ex vivo*, which have then been later transplanted as a reservoir for production of useful gene products. To date AAV and lentivirus have been used to treat Parkinson's disease using standard gene therapy technology and although AAV has been preferred for injection into humans because it does not cause any known pathology, both AAV and lentivirus appear to be safe and well-tolerated by these patients (LeWitt et al., 2011; Palfi et al., 2014). The translatability of lentivirus use is currently limited by its restricted spread in large brains; however, further modification of envelope glycoproteins or injection strategies will alleviate this clinical dilemma in the future.

The frontiers of modern biological science will be expanded by developing new biological tools and refining new technologies by collaborative research teams with skills ranging from molecular biology and viral development to functional neuroanatomy and physiology. Involvement by clinical teams will ensure that these technologies address health-related questions and are readily translated to the clinical setting to improve the health and wellbeing of patients.

## Acknowledgments

Research funded by Neurological Foundation of New Zealand (LP-B, SH), Health Research Council of New Zealand (LP-B, WA, SH), Cure Kids (SH), and the Royal Society of New Zealand Marsden Fund (WA, SH).

## References

- Abordo-Adesida, E., Follenzi, A., Barcia, C., Sciascia, S., Castro, M. G., Naldini, L., et al. (2005). Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. *Hum. Gene Ther.* 16, 741–751. doi: 10.1089/hum.2005.16.741
- Adriani, W., Boyer, F., Leo, D., Canese, R., Podo, F., Perrone-Capano, C., et al. (2010). Social withdrawal and gambling-like profile after lentiviral manipulation of DAT expression in the rat accumbens. *Int. J. Neuropsychopharmacol.* 13, 1329–1342. doi: 10.1017/S1461145709991210
- Agwuh, K. N., and MacGowan, A. (2006). Pharmacokinetics and pharmacodynamics of the tetracyclines including glycolcycylines. *J. Antimicrob. Chemother.* 58, 256–265. doi: 10.1093/jac/dkl224
- Akerblom, M., Sachdeva, R., Quintino, L., Wettergren, E. E., Chapman, K. Z., Manfre, G., et al. (2013). Visualization and genetic modification of resident brain microglia using lentiviral vectors regulated by microRNA-9. *Nat. Commun.* 4, 1770. doi: 10.1038/ncomms2801
- Annoni, A., Battaglia, M., Follenzi, A., Lombardo, A., Sergi-Sergi, L., Naldini, L., et al. (2007). The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. *Blood* 110, 1788–1796. doi: 10.1182/blood-2006-11-059873
- Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S., and Roth, B. L. (2007). Evolving the lock to fit the key to create a family of G protein-coupled receptors potentially activated by an inert ligand. *Proc. Natl. Acad. Sci. U.S.A.* 104, 5163–5168. doi: 10.1073/pnas.0700293104
- Aston-Jones, G., and Deisseroth, K. (2013). Recent advances in optogenetics and pharmacogenetics. *Brain Res.* 1511, 1–5. doi: 10.1016/j.brainres.2013.01.026
- Atasoy, D., Betley, J. N., Su, H. H., and Sternson, S. M. (2012). Deconstruction of a neural circuit for hunger. *Nature* 488, 172–177. doi: 10.1038/nature11270
- Bartholomae, C. C., Arens, A., Balaggan, K. S., Yáñez-Muñoz, R. J., Montini, E., Howe, S. J., et al. (2011). Lentiviral vector integration profiles differ in rodent postmitotic tissues. *Mol. Ther.* 19, 703–710. doi: 10.1038/mt.2011.19

- Beech, R. D., Cleary, M. A., Treloar, H. B., Eisch, A. J., Harrist, A. V., Zhong, W., et al. (2004). Nestin promoter/enhancer directs transgene expression to precursors of adult generated periglomerular neurons. *J. Comp. Neurol.* 475, 128–141. doi: 10.1002/cne.20179
- Benzekroufa, K., Liu, B. H., Teschemacher, A. G., and Kasparov, S. (2009). Targeting central serotonergic neurons with lentiviral vectors based on a transcriptional amplification strategy. *Gene Ther.* 16, 681–688. doi: 10.1038/gt.2009.7
- Blomer, U., Naldini, L., Kafri, T., Trono, D., Verma, I. M., and Gage, F. H. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. *J. Virol.* 71, 6641–6649.
- Bosch, C., Degos, B., Deniau, J. M., and Venance, L. (2011). Subthalamic nucleus high-frequency stimulation generates a concomitant synaptic excitation-inhibition in substantia nigra pars reticulata. *J. Physiol.* 589(Pt 17), 4189–4207. doi: 10.1113/jphysiol.2011.211367
- Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G., and Deisseroth, K. (2005). Millisecond-timescale, genetically targeted optical control of neural activity. *Nat. Neurosci.* 8, 1263–1268. doi: 10.1038/nn1525
- Brooks, A. R., Harkins, R. N., Wang, P., Qian, H. S., Liu, P., and Rubanyi, G. M. (2004). Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. *J. Gene Med.* 6, 395–404. doi: 10.1002/jgm.516
- Cai, D., Cohen, K. B., Luo, T., Lichtman, J. W., and Sanes, J. R. (2013). Improved tools for the Brainbow toolbox. *Nat. Methods* 10, 540–547. doi: 10.1038/nmeth.2450
- Callaway, E. M. (2008). Transneuronal circuit tracing with neurotropic viruses. *Curr. Opin. Neurobiol.* 18, 617–623. doi: 10.1016/j.conb.2009.03.007
- Carpentier, D. C., Vevis, K., Trabalza, A., Georgiadis, C., Ellison, S. M., Asfahani, R. I., et al. (2012). Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein. *Gene Ther.* 19, 761–774. doi: 10.1038/gt.2011.124
- Cetin, A., Komai, S., Eliava, M., Seeburg, P. H., and Osten, P. (2006). Stereotoxic gene delivery in the rodent brain. *Nat. Protoc.* 1, 3166–3173. doi: 10.1038/nprot.2006.450
- Chaudhury, D., Walsh, J. J., Friedman, A. K., Juarez, B., Ku, S. M., and Koo, J. W. (2013). Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. *Nature* 493, 532–536. doi: 10.1038/nature11713
- Chen, J., Kwon, C. H., Lin, L., Li, Y., and Parada, L. F. (2009). Inducible site-specific recombination in neural stem/progenitor cells. *Genesis* 47, 122–131. doi: 10.1002/dvg.20465
- Cheng, L., Jin, Z., Liu, L., Yan, Y., Li, T., Zhu, X., et al. (2004). Characterization and promoter analysis of the mouse nestin gene. *FEBS Lett.* 565, 195–202. doi: 10.1016/j.febslet.2004.03.097
- Cho, S. Y., Ravasi, L., Szajek, L. P., Seidel, J., Green, M. V., Fine, H. A., et al. (2005). Evaluation of <sup>76</sup>Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma. *J. Nucl. Med.* 46, 1923–1930.
- Chow, L. M., Zhang, J., and Baker, S. J. (2008). Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. *Transgenic Res.* 17, 919–928. doi: 10.1007/s11248-008-9185-4
- Chung, K., Wallace, J., Kim, S.-Y., Kalyanasundaram, S., Andalman, A. S., Davidson, T. J., et al. (2013). Structural and molecular interrogation of intact biological systems. *Nature* 497, 332–337. doi: 10.1038/nature12107
- Colin, A., Faideau, M., Dufour, N., Auregan, G., Hassig, R., Andrieu, T., et al. (2009). Engineered lentiviral vector targeting astrocytes in vivo. *Glia* 57, 667–679. doi: 10.1002/glia.20795
- Contag, C. H., and Bachmann, M. H. (2002). Advances in in vivo bioluminescence imaging of gene expression. *Annu. Rev. Biomed. Eng.* 4, 235–260. doi: 10.1146/annurev.bioeng.4.111901.093336
- Cronin, J., Zhang, X. Y., and Reiser, J. (2005). Altering the tropism of lentiviral vectors through pseudotyping. *Curr. Gene Ther.* 5, 387–398. doi: 10.2174/1566523054546224
- Dautan, D., Huerta-Ocampo, I., Witten, I. B., Deisseroth, K., Bolam, J. P., Gerdjikov, T., et al. (2014). A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem. *J. Neurosci.* 34, 4509–4518. doi: 10.1523/JNEUROSCI.5071-13.2014
- Deisseroth, K., and Schnitzer, M. J. (2013). Engineering approaches to illuminating brain structure and dynamics. *Neuron* 80, 568–577. doi: 10.1016/j.neuron.2013.10.032
- Delzor, A., Dufour, N., Petit, F., Guillermier, M., Houitte, D., Auregan, G., et al. (2012). Restricted transgene expression in the brain with cell-type specific neuronal promoters. *Hum. Gene Ther. Methods* 23, 242–254. doi: 10.1089/hgtb.2012.073
- De Marco, R. J., Groneberg, A. H., Yeh, C. M., Castillo Ramirez, L. A., and Ryu, S. (2013). Optogenetic elevation of endogenous glucocorticoid level in larval zebrafish. *Front. Neural Circuits* 7:82. doi: 10.3389/fncir.2013.00082
- Deroose, C. M., Reumers, V., Gijbsers, R., Bormans, G., Debyser, Z., Mortelmans, L., et al. (2006). Noninvasive monitoring of long-term lentiviral vector-mediated gene expression in rodent brain with bioluminescence imaging. *Mol. Ther.* 14, 423–431. doi: 10.1016/j.yymthe.2006.05.007
- Desai, M., Kahn, I., Knoblich, U., Bernstein, J., Atallah, H., Yang, A., et al. (2011). Mapping brain networks in awake mice using combined optical neural control and fMRI. *J. Neurophysiol.* 105, 1393–1405. doi: 10.1152/jn.00828.2010
- Desmaris, N., Bosch, A., Salaün, C., Petit, C., Prévost, M. C., Tordo, N., et al. (2001). Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. *Mol. Ther.* 4, 149–156. doi: 10.1006/mthe.2001.0431
- Diester, I., Kaufman, M. T., Mogri, M., Pashaie, R., Goo, W., Yizhar, O., et al. (2011). An optogenetic toolbox designed for primates. *Nat. Neurosci.* 14, 387–397. doi: 10.1038/nn.2749
- Dittgen, T., Nimmerjahn, A., Komai, S., Licznernski, P., Waters, J., Margrie, T. W., et al. (2004). Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 101, 18206–18211. doi: 10.1073/pnas.0407976101
- Duale, H., Kasparov, S., Paton, J. F., and Teschemacher, A. G. (2005). Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. *Exp. Physiol.* 90, 71–78. doi: 10.1113/expphysiol.2004.029173
- Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. *J. Virol.* 72, 8463–8471.
- Fanselow, E. E., and Connors, B. W. (2005). Navigating a sensorimotor loop. *Neuron* 45, 329–330. doi: 10.1016/j.neuron.2005.01.022
- Fenko, L., Yizhar, O., and Deisseroth, K. (2011). The development and application of optogenetics. *Annu. Rev. Neurosci.* 34, 389–412. doi: 10.1146/annurev-neuro-061010-113817
- Figueiredo, M., Lane, S., Tang, F., Liu, B. H., Hewinson, J., Marina, N., et al. (2011). Optogenetic experimentation on astrocytes. *Exp. Physiol.* 96, 40–50. doi: 10.1113/expphysiol.2010.052597
- Finkelshtein, D., Werman, A., Novick, D., Barak, S., and Rubinstein, M. (2013). LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. *Proc. Natl. Acad. Sci. U.S.A.* 110, 7306–7311. doi: 10.1073/pnas.1214441110
- Folcher, M., Oesterle, S., Zwicky, K., Thekkottill, T., Heymoz, J., Hohmann, M., et al. (2014). Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. *Nat. Commun.* 5, 5392. doi: 10.1038/ncomms6392
- Galvan, A., Hu, X., Smith, Y., and Wichmann, T. (2012). In vivo optogenetic control of striatal and thalamic neurons in non-human primates. *PLoS ONE* 7:e50808. doi: 10.1371/journal.pone.0050808
- Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. U.S.A.* 89, 5547–5551. doi: 10.1073/pnas.89.12.5547
- Gossen, M., and Bujard, H. (1995). Efficacy of tetracycline-controlled gene expression is influenced by cell type: commentary. *BioTechniques* 19, 213–216.
- Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., Bujard, H., et al. (1995). Transcriptional activation by tetracyclines in mammalian cells. *Science* 268, 1766–1769. doi: 10.1126/science.7792603
- Gradinaru, V., Zhang, F., Ramakrishnan, C., Mattis, J., Prakash, R., Diester, I., et al. (2010). Molecular and cellular approaches for diversifying and extending optogenetics. *Cell* 141, 154–165. doi: 10.1016/j.cell.2010.02.037
- Grinevich, V., Brecht, M., and Osten, P. (2005). Monosynaptic pathway from rat vibrissa motor cortex to facial motor neurons revealed by lentivirus-based axonal tracing. *J. Neurosci.* 25, 8250–8258. doi: 10.1523/JNEUROSCI.2235-05.2005
- Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 302, 415–419. doi: 10.1126/science.1088547
- Hama, H., Kurokawa, H., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., et al. (2011). Scale: a chemical approach for fluorescence imaging

- and reconstruction of transparent mouse brain. *Nat. Neurosci.* 14, 1481–1488. doi: 10.1038/nn.2928
- Han, X., Qian, X., Bernstein, J. G., Zhou, H. H., Franzesi, G. T., Stern, P., et al. (2009). Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. *Neuron* 62, 191–198. doi: 10.1016/j.neuron.2009.03.011
- Hasegawa, E., Yanagisawa, M., Sakurai, T., and Mieda, M. (2014). Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. *J. Clin. Invest.* 124, 604–616. doi: 10.1172/JCI71017
- Hausser, M. (2014). Optogenetics: the age of light. *Nat. Methods* 11, 1012–1014. doi: 10.1038/nmeth.3111
- Heitz, F., Johansson, T., Baumgärtel, K., Gecaj, R., Pelczar, P., and Mansuy, I. M. (2014). Heritable and inducible gene knockdown in astrocytes or neurons in vivo by a combined lentiviral and RNAi approach. *Front. Cell Neurosci.* 8:62. doi: 10.3389/fncel.2014.00062
- Hioki, H., Kameda, H., Nakamura, H., Okunomiya, T., Ohira, K., Nakamura, K., et al. (2007). Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters. *Gene Ther.* 14, 872–882. doi: 10.1038/sj.gt.3302924
- Huh, Y., Oh, M. S., Leblanc, P., and Kim, K. S. (2010). Gene transfer in the nervous system and implications for transsynaptic neuronal tracing. *Expert Opin. Biol. Ther.* 10, 763–772. doi: 10.1517/14712591003796538
- Idraccolo, S., Minuzzo, S., Feroli, F., Mammano, F., Calderazzo, F., Chiecchio Bianchi, L., et al. (1998). Pseudotyping of Moloney leukemia virus-based retroviral vectors with simian immunodeficiency virus envelope leads to targeted infection of human CD4+ lymphoid cells. *Gene Ther.* 5, 209–217. doi: 10.1038/sj.gt.3300603
- Jakobsson, J., Ericson, C., Jansson, M., Björk, E., and Lundberg, C. (2003). Targeted transgene expression in rat brain using lentiviral vectors. *J. Neurosci. Res.* 73, 876–885. doi: 10.1002/jnr.10719
- Kato, S., Kobayashi, K., Inoue, K., Kuramochi, M., Okada, T., Yaginuma, H., et al. (2011a). A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein. *Hum. Gene Ther.* 22, 197–206. doi: 10.1089/hum.2009.179
- Kato, S., Kuramochi, M., Takasumi, K., Kobayashi, K., Inoue, K., Takahara, D., et al. (2011b). Neuron-specific gene transfer through retrograde transport of lentiviral vector pseudotyped with a novel type of fusion envelope glycoprotein. *Hum. Gene Ther.* 22, 1511–1523. doi: 10.1089/hum.2011.111
- Kato, S., Kobayashi, K., and Kobayashi, K. (2014). Improved transduction efficiency of a lentiviral vector for neuron-specific retrograde gene transfer by optimizing the junction of fusion envelope glycoprotein. *J. Neurosci. Methods* 227, 151–158. doi: 10.1016/j.jneumeth.2014.02.015
- Ke, M. T., Fujimoto, S., and Imai, T. (2013). SeeDB: a simple and morphology-preserving optical clearing agent for neuronal circuit reconstruction. *Nat. Neurosci.* 16, 1154–1161. doi: 10.1038/nn.3447
- Klaw, M. C., Xu, C., and Tom, V. J. (2013). Intraspinal AAV injections immediately rostral to a thoracic spinal cord injury site efficiently transduces neurons in spinal cord and brain. *Mol. Ther. Nucleic Acids* 2:e108. doi: 10.1038/mtna.2013.34
- Klein, R. L., Meyer, E. M., Peel, A. L., Zolotukhin, S., Meyers, C., Muzyczka, N., et al. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. *Exp. Neurol.* 150, 183–194. doi: 10.1006/exnr.1997.6736
- Knöpfel, T. (2012). Genetically encoded optical indicators for the analysis of neuronal circuits. *Nat. Rev. Neurosci.* 13, 687–700. doi: 10.1038/nrn3293
- Konermann, S., Brigham, M. D., Trevino, A. E., Hsu, P. D., Heidenreich, M., Cong, L., et al. (2013). Optical control of mammalian endogenous transcription and epigenetic states. *Nature* 500, 472–476. doi: 10.1038/nature12466
- Kumar-Singh, R. (2008). Barriers for retinal gene therapy: separating fact from fiction. *Vision Res.* 48, 1671–1680. doi: 10.1016/j.visres.2008.05.005
- Lee, J. H., Durand, R., Gradinaru, V., Zhang, F., Goshen, I., Kim, D.-S., et al. (2010). Global and local fMRI signals driven by neurons defined optogenetically by type and wiring. *Nature* 465, 788–792. doi: 10.1038/nature09108
- Lerchner, W., Corgiat, B., Der Minassian, V., Saunders, R. C., and Richmond, B. J. (2014). Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain. *Gene Ther.* 21, 233–241. doi: 10.1038/gt.2013.75
- LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol.* 10, 309–319. doi: 10.1016/S1474-4422(11)70039-4
- Li, M., Husic, N., Lin, Y., Christensen, H., Malik, I., McIver, S., et al. (2010). Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. *J. Neurosci. Methods* 189, 56–64. doi: 10.1016/j.jneumeth.2010.03.019
- Li, Y., Du, X. F., and Du, J. L. (2013). Resting microglia respond to and regulate neuronal activity in vivo. *Commun. Integr. Biol.* 6:e24493. doi: 10.4161/cib.24493
- Linterman, K. S., Palmer, D. N., Kay, G. W., Barry, L. A., Mitchell, N. L., McFarlane, R. G., et al. (2011). Lentiviral-mediated gene transfer to the sheep brain: implications for gene therapy in Batten disease. *Hum. Gene Ther.* 22, 1011–1020. doi: 10.1089/hum.2011.026
- Liu, K. C., Lin, B. S., Gao, A. D., Ma, H. Y., Zhao, M., Zhang, R., et al. (2014). Integrase-deficient lentivirus: opportunities and challenges for human gene therapy. *Curr. Gene Ther.* 14, 352–364. doi: 10.2174/1566523214666140825124311
- Liu, Y. J., Ehrenguber, M. U., Negwer, M., Shao, H. J., Cetin, A. H., and Lyon, D. C. (2013). Tracing inputs to inhibitory or excitatory neurons of mouse and cat visual cortex with a targeted rabies virus. *Curr. Biol.* 23, 1746–1755. doi: 10.1016/j.cub.2013.07.033
- Lobbestael, E., Reumers, V., Ibrahimi, A., Paesen, K., Thiry, I., Gijsbers, R., et al. (2010). Immunohistochemical detection of transgene expression in the brain using small epitope tags. *BMC Biotechnol.* 10:16. doi: 10.1186/1472-6750-10-16
- Massoud, T. F., Singh, A., and Gambhir, S. S. (2008). Noninvasive molecular neuroimaging using reporter genes: part I, principles revisited. *AJNR Am. J. Neuroradiol.* 29, 229–234. doi: 10.3174/ajnr.A0864
- Mazarakis, N. D., Azzouz, M., Rohll, J. B., Ellard, F. M., Wilkes, F. J., Olsen, A. L., et al. (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. *Hum. Mol. Genet.* 10, 2109–2121. doi: 10.1093/hmg/10.19.2109
- McIver, S. R., Lee, C. S., Lee, J. M., Green, S. H., Sands, M. S., Snider, B. J., et al. (2005). Lentiviral transduction of murine oligodendrocytes in vivo. *J. Neurosci. Res.* 82, 397–403. doi: 10.1002/jnr.20626
- McIver, S. R., Muccigrosso, M., Gonzales, E. R., Lee, J. M., Roberts, M. S., Sands, M. S., et al. (2010). Oligodendrocyte degeneration and recovery after focal cerebral ischemia. *Neuroscience* 169, 1364–1375. doi: 10.1016/j.neuroscience.2010.04.070
- Mittmann, W., Wallace, D. J., Czubyak, U., Herb, J. T., Schaefer, A. T., Looger, L. L., et al. (2011). Two-photon calcium imaging of evoked activity from L5 somatosensory neurons in vivo. *Nat. Neurosci.* 14, 1089–1093. doi: 10.1038/nn.2879
- Miyashita, T., Shao, Y. R., Chung, J., Pourzia, O., and Feldman, D. E. (2013). Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex. *Front. Neural Circuits* 7:8. doi: 10.3389/fncir.2013.00008
- Miyoshi, H., Takahashi, M., Gage, F. H., and Verma, I. M. (1997). Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. *Proc. Natl. Acad. Sci. U.S.A.* 94, 10319–10323. doi: 10.1073/pnas.94.19.10319
- Naldini, L. (1998). Lentiviruses as gene transfer agents for delivery to non-dividing cells. *Curr. Opin. Biotechnol.* 9, 457–463. doi: 10.1016/S0958-1669(98)80029-3
- Nathanson, J. L., Yanagawa, Y., Obata, K., and Callaway, E. M. (2009). Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. *Neuroscience* 161, 441–450. doi: 10.1016/j.neuroscience.2009.03.032
- Nielsen, T. T., Marion, I., Hasholt, L., and Lundberg, C. (2009). Neuron-specific RNA interference using lentiviral vectors. *J. Gene Med.* 11, 559–569. doi: 10.1002/jgm.1333
- Packer, A. M., Roska, B., and Häusser, M. (2013). Targeting neurons and photons for optogenetics. *Nat. Neurosci.* 16, 805–815. doi: 10.1038/nn.3427
- Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavis, S., Buttery, P. C., et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. *Lancet* 383, 1138–1146. doi: 10.1016/S0140-6736(13)61939-X
- Pastrana, E. (2011). Perfecting ChR2. *Nat. Methods* 8, 447. doi: 10.1038/nmeth0611-447



- Pathak, G. P., Vrana, J. D., and Tucker, C. L. (2013). Optogenetic control of cell function using engineered photoreceptors. *Biol. Cell* 105, 59–72. doi: 10.1111/boc.201200056
- Pluta, K., Luce, M. J., Bao, L., Agha-Mohammadi, S., and Reiser, J. (2005). Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. *J. Gene Med.* 7, 803–817. doi: 10.1002/jgm.712
- Pollock, J. D., Wu, D. Y., and Satterlee, J. S. (2014). Molecular neuroanatomy: a generation of progress. *Trends Neurosci.* 37, 106–123. doi: 10.1016/j.tins.2013.11.001
- Qin, J. Y., Zhang, L., Clift, K. L., Hulur, I., Xiang, A. P., Ren, B.-Z., et al. (2010). Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. *PLoS ONE* 5:e10611. doi: 10.1371/journal.pone.0010611
- Rogan, S. C., and Roth, B. L. (2011). Remote control of neuronal signaling. *Pharmacol. Rev.* 63, 291–315. doi: 10.1124/pr.110.003020
- Sauer, B., and Henderson, N. (1988). Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. *Proc. Natl. Acad. Sci. U.S.A.* 85, 5166–5170. doi: 10.1073/pnas.85.14.5166
- Schoderboeck, L., Riad, S., Bokor, A. M., Wicky, H. E., Strauss, M., Bostina, M., et al. (2015). Chimeric rabies SADB19-VSVg pseudotyped lentiviral vectors mediate long-range retrograde transduction from the mouse spinal cord. *Gene Ther.* doi: 10.1038/gt.2015.3 [Epub ahead of print].
- Scotto-Lomassese, S., Nissant, A., Mota, T., Néant-Féry, M., Oostra, B. A., Greer, C. A., et al. (2011). Fragile X mental retardation protein regulates new neuron differentiation in the adult olfactory bulb. *J. Neurosci.* 31, 2205–2215. doi: 10.1523/JNEUROSCI.5514-10.2011
- Seeger-Armbruster, S., Bosch-Bouju, C., Little, S. T., Smither, R. A., Hughes, S. M., Hyland, B. I., et al. (2015). Patterned, but not tonic, optogenetic stimulation in motor thalamus improves reaching in acute drug-induced parkinsonian rats. *J. Neurosci.* 35, 1211–1216. doi: 10.1523/JNEUROSCI.3277-14.2015
- Shah, K., Hingtgen, S., Kasmieh, R., Figueiredo, J. L., Garcia-Garcia, E., Martinez-Serrano, A., et al. (2008). Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. *J. Neurosci.* 28, 4406–4413. doi: 10.1523/JNEUROSCI.0296-08.2008
- Shu, X., Lev-Ram, V., Deerinck, T. J., Qi, Y., Ramko, E. B., Davidson, M. W., et al. (2011). A genetically encoded tag for correlated light and electron microscopy of intact cells, tissues, and organisms. *PLoS Biol.* 9:e1001041. doi: 10.1371/journal.pbio.1001041
- Sohal, V. S., Zhang, F., Yizhar, O., and Deisseroth, K. (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. *Nature* 459, 698–702. doi: 10.1038/nature07991
- Sosinsky, G. E., Giepmans, B. N., Deerinck, T. J., Gaietta, G. M., and Ellisman, M. H. (2007). Markers for correlated light and electron microscopy. *Methods Cell Biol.* 79, 575–591. doi: 10.1016/S0091-679X(06)79023-9
- Stern, P., Astrof, S., Erkeland, S. J., Schustak, J., Sharp, P. A., and Hynes, R. O. (2008). A system for Cre-regulated RNA interference in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 105, 13895–13900. doi: 10.1073/pnas.0806907105
- Sun, M. Y., Yetman, M. J., Lee, T.-C., Chen, Y., and Jankowsky, J. L. (2014). Specificity and efficiency of reporter expression in adult neural progenitors vary substantially among nestin-CreER(T2) lines. *J. Comp. Neurol.* 522, 1191–1208. doi: 10.1002/cne.23497
- Takada, M., Inoue, K., Koketsu, D., Kato, S., Kobayashi, K., and Nambu, A. (2013). Elucidating information processing in primate basal ganglia circuitry: a novel technique for pathway-selective ablation mediated by immunotoxin. *Front. Neural Circuits* 7:140. doi: 10.3389/fncir.2013.00140
- Thanos, P. K., Robison, L., Nestler, E. J., Kim, R., Michaelides, M., Lobo, M. K., et al. (2013). Mapping brain metabolic connectivity in awake rats with muPET and optogenetic stimulation. *J. Neurosci.* 33, 6343–6349. doi: 10.1523/JNEUROSCI.4997-12.2013
- Tomer, R., Ye, L., Hsueh, B., and Deisseroth, K. (2014). Advanced CLARITY for rapid and high-resolution imaging of intact tissues. *Nat. Protoc.* 9, 1682–1697. doi: 10.1038/nprot.2014.123
- Trabalza, A., Georgiadis, C., Eleftheriadou, I., Hislop, J. N., Ellison, S. M., Karavassilis, M. E., et al. (2013). Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors. *Gene Ther.* 20, 723–732. doi: 10.1038/gt.2012.85
- Trono, D. (2000). Lentiviral vectors: turning a deadly foe into a therapeutic agent. *Gene Ther.* 7, 20–23. doi: 10.1038/sj.gt.3301105
- Tye, K. M., and Deisseroth, K. (2012). Optogenetic investigation of neural circuits underlying brain disease in animal models. *Nat. Rev. Neurosci.* 13, 251–266. doi: 10.1038/nrn3171
- van Hooijdonk, L. W., Ichwan, M., Dijkmans, T. F., Schouten, T. G., de Backer, M. W. A., Adan, R. A. H., et al. (2009). Lentivirus-mediated transgene delivery to the hippocampus reveals sub-field specific differences in expression. *BMC Neurosci.* 10:2. doi: 10.1186/1471-2202-10-2
- Verma, I. M., and Somia, N. (1997). Gene therapy – promises, problems and prospects. *Nature* 389, 239–242. doi: 10.1038/38410
- Vigna, E., and Naldini, L. (2000). Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. *J. Gene Med.* 2, 308–316. doi: 10.1002/1521-2254(200009/10)2:5<308::AID-JGM131>3.0.CO;2-3
- Vodicka, M. A. (2001). Determinants for lentiviral infection of non-dividing cells. *Somat. Cell Mol. Genet.* 26, 35–49. doi: 10.1023/A:1021022629126
- Wang, X., Chen, X., and Yang, Y. (2012). Spatiotemporal control of gene expression by a light-switchable transgene system. *Nat. Methods* 9, 266–269. doi: 10.1038/nmeth.1892
- Watanabe, S., Davis, M. W., and Jorgenson, E. M. (2014). Flash-and-freeze electron microscopy: coupling optogenetics with high-pressure freezing. *Nanoscale Imag. Synop.* 84, 43–57. doi: 10.1007/978-1-4614-9179-8\_3
- Watson, D. J., Kobinger, G. P., Passini, M. A., Wilson, J. M., and Wolfe, J. H. (2002). Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. *Mol. Ther.* 5(Pt 1), 528–537. doi: 10.1006/mthe.2002.0584
- Weber, B. (2012). Neuroscience: the case for brain imaging technology. *Nature* 483, 541. doi: 10.1038/483541d
- Willnow, T. E. (1999). The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. *J. Mol. Med. (Berl.)* 77, 306–315. doi: 10.1007/s001090050356
- Wiznerowicz, M., and Trono, D. (2003). Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. *J. Virol.* 77, 8957–8961. doi: 10.1128/JVI.77.16.8957-8951.2003
- Yaguchi, M., Ohashi, Y., Tsubota, T., Sato, A., Koyano, K. W., Wang, N., et al. (2013). Characterization of the properties of seven promoters in the motor cortex of rats and monkeys after lentiviral vector-mediated gene transfer. *Hum. Gene Ther. Methods* 24, 333–344. doi: 10.1089/hgtb.2012.238
- Yang, B., Treweek, J. B., Kulkarni, R. P., Deverman, B. E., Chen, C.-K., Lubeck, E., et al. (2014). Single-cell phenotyping within transparent intact tissue through whole-body clearing. *Cell* 158, 945–958. doi: 10.1016/j.cell.2014.07.017
- Zhang, F., Aravanis, A. M., Adamantidis, A., de Lecea, L., and Deisseroth, K. (2007). Circuit-breakers: optical technologies for probing neural signals and systems. *Nat. Rev. Neurosci.* 8, 577–581. doi: 10.1038/nrn2192
- Zhang, F., Gradinaru, V., Adamantidis, A. R., Durand, R., Airan, R. D., de Lecea, L., et al. (2010). Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. *Nat. Protoc.* 5, 439–456. doi: 10.1038/nprot.2009.226
- Zhou, S., Mody, D., DeRavin, S. S., Hauer, J., Lu, T., Ma, Z., et al. (2010). A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. *Blood* 116, 900–908. doi: 10.1182/blood-2009-10-250209

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Parr-Brownlie, Bosch-Bouju, Schoderboeck, Sizemore, Abraham and Hughes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.